AxCellerate supports neurotoxicity assessment with human-relevant Brain-on-Chip models for preclinical safety testing and neuronal response analysis.
Understanding the potential neurotoxic effects of a compound is a critical step in preclinical research, safety assessment and product development.
Conventional testing systems can provide useful information, but they may not fully reflect the complexity of human neuronal biology. This can limit the ability to detect early effects on neuronal activity, network function or biological response.
AxCellerate provides neurotoxicity assessment services based on Brain-on-Chip technology and three-dimensional human-derived neuronal models. The platform is designed to support the evaluation of potential adverse effects in a more human-relevant in vitro environment, helping research teams generate additional evidence before moving to further development or testing stages.
AxCellerate’s Brain-on-Chip platform enables the study of neuronal response in advanced three-dimensional models, supporting safety-related questions across different research and industry contexts.
The technology can help by providing:
Three-dimensional human-derived neuronal models offer a more relevant environment to investigate potential effects on neuronal activity and biological response.
Electrophysiological recording capabilities support the observation of neuronal network activity and help identify functional changes after compound exposure.
The platform can support the identification of safety signals or neurotoxic effects earlier in the development or assessment process.
AxCellerate’s models allow compounds, ingredients or substances to be assessed in a controlled experimental setting, with project-specific conditions and readouts.
The service can generate additional preclinical evidence to complement existing safety assessment workflows and internal decision-making.
Advantages
AxCellerate offers a specialized approach for organizations that need to investigate neuronal safety and potential adverse effects in a more advanced preclinical model.
By integrating Brain-on-Chip technology into neurotoxicity assessment, AxCellerate helps research teams and industry partners better understand potential risks and make more informed decisions.
